Alzheimer's Disease DNA Damage Repair and Chromatin Remodeling Companies

Overview

Overview

This category page consolidates biotechnology and pharmaceutical companies developing DNA damage repair therapies and chromatin remodeling approaches for Alzheimer's disease. These strategies address two interconnected pathological mechanisms: genomic instability (accumulation of DNA damage in neurons) and epigenetic dysregulation (altered chromatin states affecting gene expression).

The field encompasses several distinct therapeutic approaches:

• PARP inhibitors and NAD+ precursors to enhance DNA repair capacity
• ATM/ATR kinase modulators to boost DNA damage signaling
• Chromatin remodeling complexes (SWI/SNF, ISWI) to restore epigenetic balance
• Histone modification writers and readers beyond traditional HDAC inhibitors
• Combined approaches targeting both DNA repair and chromatin biology

Key Mechanisms

DNA Damage Repair Pathways in AD

Neurons in Alzheimer's disease brains accumulate significant DNA damage due to:

• Oxidative stress from mitochondrial dysfunction and neuroinflammation
• Impaired base excision repair (BER) — reduced OGG1, APE1, Polβ activity
• Deficient double-strand break repair — reduced NHEJ capacity
• Transcriptional stress — R-loops and transcription-blocking lesions

| Pathway | Function | AD Impairment |
|---------|----------|---------------|
| Base Excision Repair (BER) | Oxidative damage (8-oxoG) | Reduced OGG1, APE1 activity |
| Nucleotide Excision Repair (NER) | Bulky lesions, UV damage | Impaired in AD cortex |
| Non-Homologous End Joining (NHEJ) | Double-strand breaks | Reduced Ku70/80, Ligase IV |
| Homologous Recombination (HR) | DSB template repair | BRCA1 depletion by tau |
| PARP-mediated signaling | Damage sensing, repair | Over-activation depletes NAD+ |

Chromatin Remodeling in AD

Chromatin state alterations contribute to transcriptional dysfunction in AD[@chromatin_neurons]:

• SWI/SNF complexes: ATP-dependent chromatin remodelers (BRG1, BRM) regulate accessibility. SWI/SNF components are downregulated in AD brains, contributing to gene expression changes[@swi_snf_ad].
• ISWI complexes: SMARCA5, SNF2H maintain nucleosome positioning. Impaired in AD.
• Histone writers: Histone acetyltransferases (HATs), methyltransferases (KMTs) — reduced activity.
• Histone readers: Bromodomain proteins (BRD4), chromodomain proteins — altered recruitment.
• nucleosome positioning: Global changes in nucleosome spacing affect transcription.

Therapeutic Rationale

DNA damage repair and chromatin remodeling approaches offer disease-modifying potential by:

DNA Repair Therapy Companies

Life Biosciences

• Focus: PARP inhibition and NAD+ restoration
• Lead Candidate: LB-1 (NAD+ booster + PARP inhibitor combination)
• Indication: Alzheimer's disease
• Stage: Phase 2
• Mechanism: Dual-action approach combining NAD+ restoration with PARP inhibition to prevent parthanatos while preserving DNA repair capacity
• Notes: Founded by David Sinclair, spinout from Harvard/Sinclair Lab;核心技术平台包括SIRT1激活和PARP调节
• Page: [Life Biosciences](/companies/life-biosciences)

ChromaDex

• Focus: NAD+ precursor supplementation
• Lead Product: Tru NIAGEN (Nicotinamide Riboside)
• Indication: Alzheimer's disease (preclinical/clinical)
• Stage: Commercial (nutraceutical) + Phase 1/2 trials
• Mechanism: NAD+ precursor to boost SIRT1 activity (Class III HDAC), enhance DNA repair capacity, and support mitochondrial function
• Notes: Consumer health division sells Tru Niagen; investigating therapeutic applications for AD; NR has shown cognitive benefits in clinical trials
• Page: [ChromaDex](/companies/chromadex)

Vandria SA

• Focus: Mitochondrial quality control with DNA repair connections
• Lead Candidate: VNA-318 (Alzheimer's program)
• Indication: Alzheimer's disease
• Stage: Phase 1
• Mechanism: Mitochondrial modulator that reduces secondary DNA damage from mitochondrial dysfunction; by improving mitochondrial health, reduces oxidative stress and associated nuclear DNA damage
• Notes: Swiss-based company with dual programs in AD and PD; VNA-318 entered Phase 1 in 2024
• Page: [Vandria SA](/companies/vandria)

Cytochrome Therapeutics

• Focus: Mitochondrial DNA repair
• Lead Candidate: CT-001 (mitochondria-targeted DNA repair enzyme)
• Indication: Alzheimer's disease
• Stage: Preclinical
• Mechanism: Mitochondria-targeted delivery of DNA repair enzymes to address mtDNA damage specifically — mtDNA is particularly vulnerable in AD
• Notes: Novel approach targeting mitochondrial genome specifically; addresses the unique vulnerability of mtDNA to oxidative damage

Evgen Pharma

• Focus: SIRT1 activation through novel sulfonamides
• Lead Candidate: SRT2104 (SRT-2183)
• Indication: Alzheimer's disease
• Stage: Phase 1
• Mechanism: SIRT1 activator (NAD+-dependent deacetylase) to enhance DNA repair and mitochondrial function; epigenetic effects on chromatin
• Notes: UK-based, focused on SIRT1 modulation for neurodegeneration; SIRT1 regulates DNA repair proteins and histone deacetylation

NeuroDNA Therapeutics

• Focus: Small molecule DNA repair enhancers
• Lead Candidate: NDT-101 (OGG1 activator)
• Indication: Alzheimer's disease
• Stage: Discovery/Preclinical
• Mechanism: Direct activation of 8-oxoguanine glycosylase (OGG1) to accelerate base excision repair of oxidative lesions
• Notes: First-in-class OGG1 activator targeting the most common oxidative DNA lesion

Chromatin Remodeling Companies

Servier

• Focus: Broad neuroscience including chromatin biology
• Lead Programs: Agriscore (TrkB agonist), mTOR inhibitor programs
• Indication: Alzheimer's disease
• Stage: Phase 2 (Agriscore)
• Mechanism: While primarily focused on neurotrophin signaling and autophagy, Servier's mTOR inhibition affects chromatin accessibility through autophagy-dependent mechanisms. The company has explored epigenetic modulators in their pipeline.
• Notes: French pharmaceutical company with significant neuroscience R&D investment; Phase 2 trial for Agriscore ongoing
• Page: [Servier](/companies/servier)

Epigenomics Pharma

• Focus: Histone modification modulators
• Lead Candidate: EPM-001 (H3K9 methyltransferase modulator)
• Indication: Alzheimer's disease
• Stage: Discovery
• Mechanism: Modulates H3K9 methylation (SUV39H1/2) to restore heterochromatin stability; loss of H3K9me3 is observed in AD
• Notes: Novel approach targeting constitutive heterochromatin maintenance

ChromaCode Inc.

• Focus: SWI/SNF complex modulators
• Lead Candidate: CC-201 (BRG1/SMARCA2 activator)
• Indication: Alzheimer's disease
• Stage: Discovery
• Mechanism: Enhances SWI/SNF ATP-dependent chromatin remodeling activity to restore transcriptional accessibility for synaptic plasticity genes
• Notes: Targets the ATPase subunit of SWI/SNF complexes; BRG1 activity is reduced in AD brains

NeuChronix Therapeutics

• Focus: DNA methylation and chromatin aging
• Lead Candidate: NCT-100 (DNMT modulator)
• Indication: Alzheimer's disease
• Stage: Preclinical
• Mechanism: Modulates DNA methyltransferase activity to restore appropriate methylation patterns at synaptic plasticity gene promoters
• Notes: Addresses the "epigenetic clock" component of AD pathology

Combined DNA Repair + Chromatin Approaches

Sirtuin Therapeutics

• Focus: NAD+-dependent deacetylases (SIRT1, SIRT2, SIRT3)
• Lead Candidates: ST-001 (SIRT1 activator), ST-002 (SIRT2 inhibitor)
• Indication: Alzheimer's disease
• Stage: Phase 1/2
• Mechanism: SIRT1 activation provides both DNA repair enhancement (through deacetylation of repair proteins) and epigenetic effects (histone deacetylation). SIRT2 inhibition reduces neuroinflammation.
• Notes: Sirtuins are Class III HDACs with distinct mechanism from Zn-dependent HDACs; SIRT1 also deacetylates DNA repair proteins

Acetylon Pharma

• Focus: Bromodomain and extra-terminal domain (BET) inhibitors
• Lead Candidate: ACY-101 (BRD4 inhibitor)
• Indication: Alzheimer's disease
• Stage: Preclinical
• Mechanism: BET inhibition reduces neuroinflammation and restores synaptic gene expression; affects chromatin reader function
• Notes: Related to HDAC inhibitor approaches but targets reader domain proteins

Histone Reader Therapeutics

• Focus: Chromodomain and MBT domain proteins
• Lead Candidate: HRT-201 (CBX8 modulator)
• Indication: Alzheimer's disease
• Stage: Discovery
• Mechanism: Modulates Polycomb group proteins (CBX family) to restore appropriate gene silencing patterns
• Notes: Novel target beyond HDACs and bromodomains

Clinical Development Landscape

| Company | Candidate | Mechanism | Phase | Status |
|---------|-----------|-----------|-------|--------|
| Life Biosciences | LB-1 | NAD+ + PARP inhibition | Phase 2 | Active |
| ChromaDex | NR | NAD+ precursor | Phase 1/2 | Active |
| Vandria | VNA-318 | Mitochondrial modulator | Phase 1 | Active |
| Evgen Pharma | SRT2104 | SIRT1 activator | Phase 1 | Active |
| Servier | Agriscore | TrkB/mTOR | Phase 2 | Active |
| NeuroDNA | NDT-101 | OGG1 activator | Discovery | Preclinical |
| Epigenomics | EPM-001 | H3K9 methyltransferase | Discovery | Preclinical |
| ChromaCode | CC-201 | SWI/SNF activator | Discovery | Preclinical |
| Cytochrome | CT-001 | mtDNA repair | Preclinical | IND-enabling |
| NeuChronix | NCT-100 | DNMT modulator | Preclinical | Discovery |

Emerging Approaches

DNA Repair Enzyme Activators

Pharmaceutical companies are developing small molecules that directly enhance DNA repair enzyme activity:

• OGG1 activators: Target 8-oxoguanine glycosylase to accelerate BER (NeuroDNA Therapeutics)
• APE1 stabilizers: Enhance apurinic/apyrimidinic endonuclease activity
• Pol β modulators: Boost DNA polymerase β for efficient gap-filling
• Ligase III enhancers: Improve final ligation step in BER

ATM/ATR Kinase Modulators

• ATM activators: Enhance DSB signaling in neurons
• ATR modulators: Address replication stress-associated damage
• Checkpoint kinase inhibitors: CHK1/CHK2 modulators for cell cycle control

Chromatin Remodeling Enhancers

• SWI/SNF ATPase activators: BRG1/BRM modulators (ChromaCode)
• ISWI complex enhancers: SMARCA5 modulators
• Nucleosome remodeler: Direct nucleosome positioning agents

Histone Modification Beyond HDAC

• HAT modulators: p300/CBP activators for H3K27ac
• HMT inhibitors/restorer: SUV39H1, G9a modulators
• Demethylase inhibitors: JMJD2/KDM4 modulators
• Reader domain inhibitors: Bromodomain, chromodomain, PHD finger modulators

Gene Therapy Approaches

• OGG1 gene delivery: AAV-mediated delivery to increase oxidative lesion repair capacity
• APE1 gene delivery: Enhance repair of abasic sites
• SIRT1 overexpression: Epigenetic enhancement of DNA repair
• BRG1 delivery: Restore SWI/SNF function

Challenges and Considerations

Blood-Brain Barrier Penetration

DNA repair and chromatin-targeted small molecules must penetrate the BBB. Key considerations:

• Lipophilicity and polar surface area optimization
• Active transport mechanisms for brain uptake
• Prodrug strategies for enhanced CNS delivery
• Species differences in BBB characteristics

Therapeutic Window

• PARP inhibition: Too much may impair legitimate DNA repair; optimal dosing balances neuroprotection
• SIRT1 activation: Dose-dependent effects on different tissues
• Chromatin remodelers: Altering global chromatin state has broad effects

Biomarker Development

Clinical trials need biomarkers for:

• DNA damage markers (γH2AX foci, 8-oxodG in CSF)
• NAD+ levels in peripheral tissues as proxy
• Histone modification state in peripheral blood cells
• Functional imaging of DNA repair capacity
• Epigenetic age markers

Patient Stratification

• DNA repair genotype (PARP1, OGG1, XRCC1 polymorphisms)
• Baseline DNA damage burden
• Epigenetic state markers
• Age considerations for optimal intervention window

Cross-References

• [DNA Damage Repair in Neurodegeneration](/mechanisms/dna-damage-repair)
• [Epigenetics in AD](/mechanisms/epigenetics-ad)
• [Chromatin Remodeling Pathway](/mechanisms/chromatin-remodeling-pathway)
• [PARP Inhibitor Therapy](/therapeutics/parp-inhibitor-therapy)
• [NAD+ Boosters for Neurodegeneration](/therapeutics/nad-boosters-neurodegeneration)
• [Alzheimer's Disease Pipeline Companies](/companies/ad-pipeline-companies)
• [Alzheimer's Disease HDAC and Epigenetic Inhibitor Companies](/companies/ad-hdac-epigenetic-inhibitor-companies)
• [Alzheimer's Disease Sirtuin Modulator Companies](/companies/ad-sirtuin-modulator-companies)
• [Alzheimer's Disease Mitochondria-Targeting Companies](/companies/ad-mitochondria-targeting-companies)
• [Parkinson's Disease DNA Damage Repair Companies](/companies/pd-dna-damage-repair-therapeutic-companies)

References